Literature DB >> 22009003

Endothelial cell function in patients with hereditary angioedema: elevated soluble E-selectin level during inter-attack periods.

Judit Czúcz1, Gyula Schaffer, Dorottya Csuka, Szilvia Walentin, Jan Kunde, Zoltán Prohászka, Henriette Farkas, László Cervenak.   

Abstract

BACKGROUND: The bradykinin pathway in the pathomechanism of hereditary angioedema due to C1-inhibitor deficiency (henceforward "hereditary angioedema") has been thoroughly studied; however, much less is known about endothelial cell function. Enhanced endothelial cell permeability is obvious during edematous attacks, but not during inter-attack periods. Our knowledge about other endothelial characteristics is even more incomplete.
OBJECTIVE: Therefore the aim of this study was to characterize endothelial cell function in hereditary angioedema patients during symptom-free, inter-attack periods.
METHODS: We measured the serum levels of soluble E-selectin, endothelin-1, and von Willebrand factor along with collagen-binding activity in 49 hereditary angioedema patients and in 50 healthy controls.
RESULTS: Endothelin-1 and von Willebrand factor level, as well as its collagen-binding activity, were similar in hereditary angioedema patients and in controls; however, we found elevated soluble E-selectin levels in the patients. Interestingly, soluble E-selectin concentration did not correlate with any of the inflammatory markers or smoking, and it is not the consequence of the known E-selectin/C1-inhibitor interaction (an analytical phenomenon). In a multiple logistic regression model, the difference in soluble E-selectin between hereditary angioedema patients and controls remained highly significant when adjusted for age, gender, smoking, C-reactive protein, and AB0 blood groups.
CONCLUSION: These results demonstrate that in hereditary angioedema, the majority of endothelial functions are normal during inter-attack periods; however, soluble E-selectin levels are elevated. The higher soluble E-selectin plasma concentration is unlikely to result from inflammation; rather, it reflects enhanced shedding mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009003     DOI: 10.1007/s10875-011-9606-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  38 in total

1.  Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells.

Authors:  R Pigott; L P Dillon; I H Hemingway; A J Gearing
Journal:  Biochem Biophys Res Commun       Date:  1992-09-16       Impact factor: 3.575

2.  Increased level of soluble E-selectin in the serum from patients with idiopathic pulmonary fibrosis.

Authors:  Seiji Hayashi; Kin'ya Abe; Hiroto Matsuoka; Sho Goya; Hiroshi Morishita; Masahide Mori; Toru Arai; Hiroshi Kida; Kazumi Nishino; Yoshito Takeda; Tadashi Osaki; Isao Tachibana; Kentaro Kimura; Soichiro Yokota; Yoshikazu Inoue; Mitsunori Sakatani
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

3.  Human soluble E-selectin immunoadhesin inhibits leukemic monocyte adhesion to endothelial cells.

Authors:  Bong Hwan Sung; Sung Hyun Kim; Myeong Gu Yeo; Jin-Kyoo Kim; Woo Keun Song
Journal:  Cell Biochem Funct       Date:  2007 Sep-Oct       Impact factor: 3.685

4.  Elastase activity enhances the adhesion of neutrophil and cancer cells to vascular endothelial cells.

Authors:  F Nozawa; M Hirota; A Okabe; M Shibata; T Iwamura; Y Haga; M Ogawa
Journal:  J Surg Res       Date:  2000-12       Impact factor: 2.192

5.  A prospective study of the sensitivity, specificity and diagnostic performance of soluble intercellular adhesion molecule 1, highly sensitive C-reactive protein, soluble E-selectin and serum amyloid A in the diagnosis of neonatal infection.

Authors:  J David M Edgar; Vanessa Gabriel; J Ruth Gallimore; Stanley A McMillan; Judith Grant
Journal:  BMC Pediatr       Date:  2010-04-16       Impact factor: 2.125

6.  Increased plasma level of soluble E-selectin in acute myocardial infarction.

Authors:  H Suefuji; H Ogawa; H Yasue; T Sakamoto; Y Miyao; K Kaikita; H Soejima; K Misumi; S Miyamoto; K Kataoka
Journal:  Am Heart J       Date:  2000-08       Impact factor: 4.749

7.  Levels of soluble E-selectin and ICAM-1 in the coronary circulation of patients with stable coronary artery disease: association with the severity of coronary atherosclerosis.

Authors:  Akimitsu Nasuno; Taku Matsubara; Tomoyuki Hori; Kotaro Higuchi; Shunsuke Imai; Iwao Nakagawa; Keiichi Tsuchida; Kazuyuki Ozaki; Tohru Mezaki; Takayuki Tanaka; Ichiro Fuse; Yoshifusa Aizawa
Journal:  Jpn Heart J       Date:  2002-03

8.  Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion.

Authors:  Shenghe Cai; Alvin E Davis
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

9.  Association of cardiovascular risk factors with markers of endothelial dysfunction in middle-aged men and women. Results from the MONICA/KORA Augsburg Study.

Authors:  Barbara Thorand; Jens Baumert; Angela Döring; Andrea Schneider; Lloyd Chambless; Hannelore Löwel; Hubert Kolb; Wolfgang Koenig
Journal:  Thromb Haemost       Date:  2006-01       Impact factor: 5.249

10.  Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin.

Authors:  Andrew D Paterson; Maria F Lopes-Virella; Daryl Waggott; Andrew P Boright; S Mohsen Hosseini; Rickey E Carter; Enqing Shen; Lucia Mirea; Bhupinder Bharaj; Lei Sun; Shelley B Bull
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-03       Impact factor: 8.311

View more
  8 in total

Review 1.  HAE Pathophysiology and Underlying Mechanisms.

Authors:  Bruce L Zuraw; Sandra C Christiansen
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

2.  Novel Vasoregulatory Aspects of Hereditary Angioedema: the Role of Arginine Vasopressin, Adrenomedullin and Endothelin-1.

Authors:  Erika Kajdácsi; Péter K Jani; Dorottya Csuka; Lilian Varga; Zoltán Prohászka; Henriette Farkas; László Cervenak
Journal:  J Clin Immunol       Date:  2016-02-12       Impact factor: 8.317

Review 3.  "Nuts and Bolts" of Laboratory Evaluation of Angioedema.

Authors:  Henriette Farkas; Nóra Veszeli; Erika Kajdácsi; László Cervenak; Lilian Varga
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

4.  Oxidative stress markers in patients with hereditary angioedema.

Authors:  Stefano R Del Giacco; Davide Firinu; Paola Lucia Minciullo; Maria Pina Barca; Paolo Emilio Manconi; Gennaro Tartarisco; Mariateresa Cristani; Antonella Saija; Sebastiano Gangemi
Journal:  Arch Med Sci       Date:  2017-07-31       Impact factor: 3.318

5.  Impaired Endothelial Function in Hereditary Angioedema During the Symptom-Free Period.

Authors:  Davide Firinu; Pier P Bassareo; Angela M Zedda; Maria P Barca; Antonio Crisafulli; Giuseppe Mercuro; Stefano Del Giacco
Journal:  Front Physiol       Date:  2018-05-16       Impact factor: 4.566

6.  Hereditary angioedema: Assessing the hypothesis for underlying autonomic dysfunction.

Authors:  Maddalena A Wu; Francesco Casella; Francesca Perego; Chiara Suffritti; Nada Afifi Afifi; Eleonora Tobaldini; Andrea Zanichelli; Chiara Cogliati; Nicola Montano; Marco Cicardi
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

7.  Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.

Authors:  György Sinkovits; Marienn Réti; Veronika Müller; Zsolt Iványi; János Gál; László Gopcsa; Péter Reményi; Beáta Szathmáry; Botond Lakatos; János Szlávik; Ilona Bobek; Zita Z Prohászka; Zsolt Förhécz; Blanka Mező; Dorottya Csuka; Lisa Hurler; Erika Kajdácsi; László Cervenak; Petra Kiszel; Tamás Masszi; István Vályi-Nagy; Zoltán Prohászka
Journal:  Thromb Haemost       Date:  2022-01-21       Impact factor: 5.249

Review 8.  Biomarkers in Hereditary Angioedema.

Authors:  Grzegorz Porebski; Mateusz Kwitniewski; Avner Reshef
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-09       Impact factor: 8.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.